D' cont

coronary vessels or into a peripheral vein in a human patient in need of treatment for said coronary artery disease, said therapeutically effective amount being about 0.2 μg/kg to 48 μg/kg of patient weight.

D 2

3 ~~12~~. (amended) The method of claim ~~11~~ 2, further comprising the step of administering to said human patient about 10 U/kg to 80 U/kg of heparin within ~~about 0 to~~ 30 minutes ~~prior to~~ at administering said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof.

D 3

4 ~~13~~. (twice amended) The method of claim 3 ~~12~~, wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is administered into one or more coronary vessels.

D 4

5 ~~14~~. (amended) The method of claim 4 ~~13~~, wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is about 24 μg/kg to 48 μg/kg.

D 5

6 ~~15~~. (twice amended) The method of claim 3 ~~12~~ wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is administered into a peripheral vein.

D 6

7 ~~16~~. (amended) The method of claim 6 ~~15~~, wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is about 18 μg/kg to 36 μg/kg.

Not D2 D 7

8 ~~17~~. (twice amended) A method for treating a human patient for coronary artery disease, comprising administering a single unit dose of a recombinant ~~FGF-2~~ or an angiogenically active fragment or an angiogenically active mutein thereof into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for coronary artery disease, said unit dose

D7 cont comprising from about .008 mg to 7.2 mg of said recombinant FGF-2 or said angiogenically active fragment or said angiogenically active mutein thereof.

D8 ~~18~~ 8. (amended) The method of claim ~~17~~ 7, wherein said recombinant FGF-2 has the amino acid sequence of SEQ ID NO: 2.

D9 ~~24~~ 15. (amended) The method of claim ~~20~~ 11, wherein said unit dose comprises 0.3 mg to 3.5 mg of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof.

D10 ~~26~~ 17. (twice amended) A method for inducing angiogenesis in a heart of a human patient, comprising administering a single unit dose of a recombinant ~~FGF-2~~ FG or an angiogenically active fragment or an angiogenically active mutein thereof into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for coronary artery disease, said unit dose comprising from about .008 mg to 7.2 mg of said recombinant FGF-2 or said angiogenically active fragment or said angiogenically active mutein thereof.

D11 ~~27~~ 18. (amended) The method of claim ~~26~~ 17, wherein said recombinant FGF-2 has the amino acid sequence of SEQ ID NO: 2.

D12 ~~30~~ 21. (twice amended) A method for treating a human patient for a myocardial infarction, comprising administering a single unit dose of a recombinant ~~FGF-2~~ FG or an angiogenically active fragment or an angiogenically active mutein thereof into one or more coronary vessels or into a peripheral vein in said human patient, said unit dose comprising from about .008 mg to 7.2 mg of said recombinant FGF-2 or said angiogenically active fragment or said angiogenically active mutein thereof.

D13 23/~~32~~. (amended) The method of claim 22/~~31~~, wherein said recombinant FGF-2 has the amino acid sequence of SEQ ID NO: 2.

D14 24/~~33~~. (twice amended) A method for providing a human patient with relief from symptoms of angina, comprising administering a single unit dose of a recombinant ~~FGF-2~~ or an angiogenically active fragment or an angiogenically active mutein thereof into one or more coronary vessels or into a peripheral vein in a human patient in need of relief from symptoms of angina, said unit dose comprising from about 0.008 mg to 7.2 mg of said recombinant FGF-2 or said angiogenically active fragment or said angiogenically active mutein thereof.

D15 25/~~34~~. (amended) The method of claim 1/~~10~~, wherein said therapeutically effective amount of said recombinant FGF-2 or said angiogenically active fragment or said angiogenically active mutein thereof is administered by infusion.

D16 26/~~35~~. (amended) A method for treating a human patient for coronary artery disease, comprising administering a therapeutically effective amount of a recombinant ~~FGF-2~~ or an angiogenically active fragment or an angiogenically active mutein thereof by infusion into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for said coronary artery disease, said therapeutically effective amount being about 0.2 μg/kg to 48 μg/kg of patient weight.

D17 27/~~36~~. (amended) The method of claim 26/~~35~~, further comprising the step of administering to said human patient about 10 U/kg to 80 U/kg of heparin within ~~about 0 to~~ 30 minutes ~~prior to~~ administering said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof.

28/~~37~~. (amended) The method of claim 27/~~36~~, wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is administered into one or more coronary vessels.

48. (amended) The method of claim 47, wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is about 24 μg/kg to 48 μg/kg.

49. (amended) The method of claim 46 wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is administered into a peripheral vein.

50. (amended) The method of claim 49, wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is about 18 μg/kg to 36 μg/kg.

51. (amended) A method for treating a human patient for coronary artery disease comprising, administering a single unit dose of a recombinant ~~FGF-2~~ FG or an angiogenically active fragment or an angiogenically active mutein thereof by infusion into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for coronary artery disease, said unit dose comprising from about .008 mg to 7.2 mg of said recombinant FGF-2 or said angiogenically active fragment or said angiogenically active mutein thereof.

52. (amended) The method of claim 51, wherein said recombinant FGF-2 has the amino acid sequence of SEQ ID NO: 2.

---

53. (amended) The method of claim 52, wherein said unit dose comprises 0.3 mg to 3.5 mg of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof.

---

58. (amended) A method for inducing angiogenesis in a heart of a human patient, comprising administering a single unit dose of a recombinant ~~FGF-2~~ FG or an angiogenically active